ATE542813T1 - 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren - Google Patents
6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitorenInfo
- Publication number
- ATE542813T1 ATE542813T1 AT09786799T AT09786799T ATE542813T1 AT E542813 T1 ATE542813 T1 AT E542813T1 AT 09786799 T AT09786799 T AT 09786799T AT 09786799 T AT09786799 T AT 09786799T AT E542813 T1 ATE542813 T1 AT E542813T1
- Authority
- AT
- Austria
- Prior art keywords
- chk
- inhibitors
- compounds
- heterocyclylaminopyrazine
- substituted
- Prior art date
Links
- 101150050673 CHK1 gene Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8673208P | 2008-08-06 | 2008-08-06 | |
| US22942809P | 2009-07-29 | 2009-07-29 | |
| PCT/IB2009/053389 WO2010016005A1 (en) | 2008-08-06 | 2009-08-04 | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE542813T1 true ATE542813T1 (de) | 2012-02-15 |
Family
ID=41171261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09786799T ATE542813T1 (de) | 2008-08-06 | 2009-08-04 | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8518952B2 (enExample) |
| EP (1) | EP2328890B1 (enExample) |
| JP (1) | JP5576370B2 (enExample) |
| AT (1) | ATE542813T1 (enExample) |
| CA (1) | CA2731368C (enExample) |
| ES (1) | ES2378513T3 (enExample) |
| WO (1) | WO2010016005A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2376485T3 (pl) | 2008-12-19 | 2018-05-30 | Vertex Pharmaceuticals Incorporated | Pochodne pirazyny użyteczne jako inhibitory kinazy ATR |
| US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| EP2569287B1 (en) * | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| MX392542B (es) | 2011-09-30 | 2025-03-24 | Vertex Pharma | Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr. |
| HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
| KR102171706B1 (ko) | 2012-07-09 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 포스포디에스테라아제 10 효소의 억제제 |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| TWI623531B (zh) | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | 經取代反向嘧啶ｂｍｉ－１抑制劑 |
| CN103254121B (zh) * | 2013-04-08 | 2015-08-26 | 洛阳师范学院 | 一种合成(3r,4r)-n-pg-4-甲基-3-甲胺基哌啶的方法 |
| US10584115B2 (en) * | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| NZ720092A (en) | 2013-12-05 | 2019-05-31 | Pfizer | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| US9145393B2 (en) * | 2014-01-24 | 2015-09-29 | Confluence Life Sciences, Inc. | Arylpyridinone ITK inhibitors for treating inflammation and cancer |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| BR112016026150B1 (pt) | 2014-05-09 | 2019-11-05 | Pimera Inc | compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer |
| AU2016209046A1 (en) | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| CA2984183C (en) | 2015-05-01 | 2021-11-09 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
| CN105130991B (zh) * | 2015-07-10 | 2017-09-19 | 成都知普莱生物医药科技有限公司 | 一种合成骨形态发生蛋白受体抑制剂的方法 |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| AU2017222417B2 (en) | 2016-02-24 | 2020-07-09 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors |
| WO2018140648A1 (en) | 2017-01-25 | 2018-08-02 | Eric Jon Jacobsen | Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer |
| EP3601286A4 (en) | 2017-03-28 | 2020-09-23 | Pimera, Inc. | NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR |
| CN107056681B (zh) * | 2017-03-30 | 2019-10-01 | 广州白云山光华制药股份有限公司 | 一种托法替布中间体的制备方法 |
| EP3668858A1 (en) | 2017-08-14 | 2020-06-24 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives |
| CN107474047B (zh) * | 2017-08-29 | 2019-10-29 | 浙江工业大学 | 1,2,4-三唑并杂环类化合物的合成方法 |
| CN107827811B (zh) * | 2017-11-15 | 2021-01-29 | 上海皓伯化工科技有限公司 | 一种制备n-取代-1,2,3,6-四氢吡啶的方法 |
| JP2021151955A (ja) * | 2018-05-22 | 2021-09-30 | 株式会社カネカ | 光学活性−ｃｉｓ−アミノピペリジンの製造方法 |
| JP7478142B2 (ja) * | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| US12023335B2 (en) | 2018-08-17 | 2024-07-02 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| MX2022015829A (es) * | 2020-06-11 | 2023-04-05 | Chdi Foundation Inc | Compuestos heterocíclicos y agentes formadores de imágenes para formar la imagen de la proteína huntingtina. |
| WO2022026935A1 (en) * | 2020-07-31 | 2022-02-03 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| MX2024001193A (es) * | 2021-07-30 | 2024-05-15 | Childrens Hospital Med Ct | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a sarcoma felino de mcdonough (flt3) y usos de estos. |
| US20250346593A1 (en) * | 2022-06-10 | 2025-11-13 | Interline Therapeutics, Inc. | Imidazo(1,2-1)pyridine derivatives as ripk2 inhibitors |
| AR129535A1 (es) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | Derivados de carboxamida heterocíclicos bicíclicos microbiocidas |
| WO2024089191A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9722320D0 (en) * | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
| US6383744B1 (en) * | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
| JP2002526450A (ja) | 1998-09-18 | 2002-08-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｈｋ１キナーゼ阻害物質 |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| PT1144609E (pt) | 1999-08-27 | 2008-05-28 | Novartis Vaccines & Diagnostic | Oligonucleótidos anti-sentido quiméricos e suas formulações para transfecção de células |
| CA2385257A1 (en) | 1999-09-22 | 2001-03-29 | Canbas Co., Ltd. | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| MX337162B (es) | 2001-01-05 | 2016-02-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7704995B2 (en) * | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| JP4901102B2 (ja) * | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| EP1947102A1 (en) * | 2003-01-09 | 2008-07-23 | Pfizer, Inc. | Compositions comprising diazepinoindole derivatives as kinase inhibitors |
| SG161745A1 (en) | 2003-06-24 | 2010-06-29 | Pfizer Prod Inc | Processes for the preparation of 1-[(benzoimidazole-1 yl) quinolin-8-yl] piperidin-4-ylamine derivatives |
| US20080070930A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Pyrimidine and Pyrazine Derivatives |
| AU2008317406B2 (en) * | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
-
2009
- 2009-08-04 CA CA2731368A patent/CA2731368C/en not_active Expired - Fee Related
- 2009-08-04 JP JP2011521675A patent/JP5576370B2/ja not_active Expired - Fee Related
- 2009-08-04 EP EP09786799A patent/EP2328890B1/en not_active Not-in-force
- 2009-08-04 ES ES09786799T patent/ES2378513T3/es active Active
- 2009-08-04 US US13/057,558 patent/US8518952B2/en not_active Expired - Fee Related
- 2009-08-04 AT AT09786799T patent/ATE542813T1/de active
- 2009-08-04 WO PCT/IB2009/053389 patent/WO2010016005A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2378513T3 (es) | 2012-04-13 |
| CA2731368C (en) | 2013-05-14 |
| US8518952B2 (en) | 2013-08-27 |
| EP2328890B1 (en) | 2012-01-25 |
| EP2328890A1 (en) | 2011-06-08 |
| WO2010016005A1 (en) | 2010-02-11 |
| JP5576370B2 (ja) | 2014-08-20 |
| US20110144084A1 (en) | 2011-06-16 |
| JP2011530500A (ja) | 2011-12-22 |
| CA2731368A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| MY160454A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| ATE552255T1 (de) | 4-aminoindazole | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| MD4582B1 (ro) | Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
| EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| MA38050A1 (fr) | Inhibiteurs de gdf-8 | |
| UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| EA201391239A1 (ru) | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ | |
| GEP20227397B (en) | Inhibitors of influenza viruses replication | |
| PE20120495A1 (es) | 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
| MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
| EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. |